28 research outputs found
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
A next generation, pilot-scale continuous sterilization system for fermentation media
A new continuous sterilization system was designed, constructed, started up, and qualified for media sterilization for secondary metabolite cultivations, bioconversions, and enzyme production. An existing Honeywell Total Distributed Control 3000-based control system was extended using redundant High performance Process Manager controllers for 98 I/O (input/output) points. This new equipment was retrofitted into an industrial research fermentation pilot plant, designed and constructed in the early 1980s. Design strategies of this new continuous sterilizer system and the expanded control system are described and compared with the literature (including dairy and bio-waste inactivation applications) and the weaknesses of the prior installation for expected effectiveness. In addition, the reasoning behind selection of some of these improved features has been incorporated. Examples of enhancements adopted include sanitary heat exchanger (HEX) design, incorporation of a âflashâ cooling HEX, on-line calculation of F(o) and R(o), and use of field I/O modules located near the vessel to permit low-cost addition of new instrumentation. Sterilizer performance also was characterized over the expected range of operating conditions. Differences between design and observed temperature, pressure, and other profiles were quantified and investigated
The Hemopoietic Stem Cell Niche Versus the Microenvironment of the Multiple Myeloma-Tumor Initiating Cell
Multiple myeloma cells are reminiscent of hemopoietic stem cells in their strict dependence upon the bone marrow microenvironment. However, from all other points of view, multiple myeloma cells differ markedly from stem cells. The cells possess a mature phenotype and secrete antibodies, and have thus made the whole journey to maturity, while maintaining a tumor phenotype. Not much credence was given to the possibility that the bulk of plasma-like multiple myeloma tumor cells is generated from tumor-initiating cells. Although interleukin-6 is a major contributor to the formation of the tumorâs microenvironment in multiple myeloma, it is not a major factor within hemopoietic stem cell niches. The bone marrow niche for myeloma cells includes the activity of inflammatory cytokines released through osteoclastogenesis. These permit maintenance of myeloma cells within the bone marrow. In contrast, osteoclastogenesis constitutes a signal that drives hemopoietic stem cells away from their bone marrow niches. The properties of the bone marrow microenvironment, which supports myeloma cell maintenance and proliferation, is therefore markedly different from the characteristics of the hemopoietic stem cell niche. Thus, multiple myeloma presents an example of a hemopoietic tumor microenvironment that does not resemble the corresponding stem cell renewal niche
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
The histone deacetylase inhibitors (HDACi) have demonstrated anticancer efficacy across a range of malignancies, most impressively in the hematological cancers. It is uncertain whether this clinical efficacy is attributable predominantly to their ability to induce apoptosis and differentiation in the cancer cell, or to their ability to prime the cell to other pro-death stimuli such as those from the immune system. HDACi-induced apoptosis occurs through altered expression of genes encoding proteins in both intrinsic and extrinsic apoptotic pathways; through effects on the proteasome/aggresome systems; through the production of reactive oxygen species, possibly by directly inducing DNA damage; and through alterations in the tumor microenvironment. In addition HDACi increase the immunogenicity of tumor cells and modulate cytokine signaling and potentially T-cell polarization in ways that may contribute the anti-cancer effect in vivo. Here, we provide an overview of current thinking on the mechanisms of HDACi activity, with attention given to the hematological malignancies as well as scientific observations arising from the clinical trials. We also focus on the immune effects of these agents
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia
Waldenstrom macroglobulinemia (WM) is a B-cell disorder characterized by
the infiltration of lymphoplasmacytic cells into bone marrow and the
presence of an IgM monoclonal gammopathy. As part of the Third
International Workshop on WM, held October 7 to 10, 2004 in Paris,
France, a consensus panel charged with providing treatment
recommendations for WM updated its recommendations on both frontline and
salvage therapies. The panel considered encouraging results from recent
studies that addressed the use of extended-dose rituximab as well as
other treatment options: therapy with either nucleoside analogs and
alkylator agents, rituximab in combination with nucleoside analogs,
nucleoside analogs plus alkylator agents, or combination chemotherapies,
such as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or
cyclophosphamide and dexamethasone. The panel determined that these were
reasonable treatment options for WM patients and such therapeutic
approaches were likely to yield results that are at least as good as if
not better than the currently recommended use of single-agent alkylator,
nucleoside analog, or standard-dose rituximab therapy. Such approaches
were deemed to be reasonable treatment for WM patients in both the
upfront and salvage settings, though randomized studies addressing the
efficacy and toxicity of such novel approaches over previously
established standard of care options are needed
Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)âa trial by the Asian Myeloma Network
Opto-Chemical Micro-Capillary Clocks
Opto-chemical capillary clocks are presented that are based on the measurement of a colored segment in a microchannel (a capillary). Color is created by a chromogenic chemistry involving the oxidation of a (virtually colorless) leuco-dye. Poly(ethylene glycol) (PEG) is used as a solvent, and indigo and thioindigo (in their reduced leuco forms) act as oxygen-sensitive dyes. The clock is started by removing one seal at the end of the capillary. A visible color change occurs as air diffuses into the microchannel due to an irreversible color reaction. The length of the colored segment is proportional to the time elapsed. PEGs of different average molar mass affect the diffusion rate of oxygen in the microchannel and thereby affect the rate of the migration of the color front. Both temperature and relative humidity exert a strong effect. Six types of such clocks are described that enable times to be determined in the range from 1 day to 6 months, possibly of even decades